Skip to main content
Erschienen in: Supportive Care in Cancer 10/2012

01.10.2012 | Original Article

Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients

verfasst von: Koen Pardon, R. Deschepper, R. Vander Stichele, J. L. Bernheim, F. Mortier, N. Bossuyt, D. Schallier, P. Germonpré, D. Galdermans, W. Van Kerckhoven, L. Deliens, on behalf of the EOLIC-consortium

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective is to explore changes over time in the information and participation preferences of newly diagnosed stage IIIb/IV non-small-cell lung cancer patients.

Methods

Patients were recruited by physicians in 13 hospitals and interviewed every 2 months until the fourth and every 4 months until the sixth interview.

Results

Sixty-seven patients were interviewed three times. Over a period of 4 months from diagnosis, half of patients changed their information preferences for palliative care and end-of-life decisions with a possible or certain life-shortening effect (ELDs, e.g., non-treatment decisions) in both directions, from not wanting to wanting the information, but also—and as much—from wanting to no longer wanting it. The latter were more likely to be in a better physical condition. Preferences for participation in medical decision making also changed: 50% to 78%, depending on the type of decision (general, treatment, transfer or ELD), changed their preference towards wanting more or less participation. Pain seemed to be a trigger for patients wanting more involvement, which contrasts with studies suggesting that patients who are more ill tend to give up more control.

Conclusions

Doctors should regularly ask their advanced lung cancer patients how much information and participation they want because preferences do change in unexpected ways.
Literatur
1.
Zurück zum Zitat American College of Physicians Ethics Manual. Third edition (1992) Ann Intern Med 117: 947–960 American College of Physicians Ethics Manual. Third edition (1992) Ann Intern Med 117: 947–960
2.
Zurück zum Zitat Emanuel EJ, Emanuel LL (1992) Four models of the physician–patient relationship. JAMA 267:2221–2226PubMedCrossRef Emanuel EJ, Emanuel LL (1992) Four models of the physician–patient relationship. JAMA 267:2221–2226PubMedCrossRef
3.
Zurück zum Zitat Arora NK (2003) Interacting with cancer patients: the significance of physicians' communication behavior. Soc Sci Med 57:791–806PubMedCrossRef Arora NK (2003) Interacting with cancer patients: the significance of physicians' communication behavior. Soc Sci Med 57:791–806PubMedCrossRef
4.
Zurück zum Zitat Dias L, Chabner BA, Lynch TJ Jr, Penson RT (2003) Breaking bad news: a patient's perspective. Oncologist 8:587–596PubMedCrossRef Dias L, Chabner BA, Lynch TJ Jr, Penson RT (2003) Breaking bad news: a patient's perspective. Oncologist 8:587–596PubMedCrossRef
5.
Zurück zum Zitat de Haes H, Koedoot N (2003) Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns 50:43–49PubMedCrossRef de Haes H, Koedoot N (2003) Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns 50:43–49PubMedCrossRef
6.
Zurück zum Zitat Deschepper R, Bernheim JL, Vander Stichele R, Van den Block L, Michiels E, Van Der Kelen G, Mortier F, Deliens L (2008) Truth-telling at the end of life: a pilot study on the perspective of patients and professional caregivers. Patient Educ Couns 71:52–56PubMedCrossRef Deschepper R, Bernheim JL, Vander Stichele R, Van den Block L, Michiels E, Van Der Kelen G, Mortier F, Deliens L (2008) Truth-telling at the end of life: a pilot study on the perspective of patients and professional caregivers. Patient Educ Couns 71:52–56PubMedCrossRef
7.
Zurück zum Zitat de Haes H (2006) Dilemmas in patient centeredness and shared decision making: a case for vulnerability. Patient Educ Couns 62:291–298PubMedCrossRef de Haes H (2006) Dilemmas in patient centeredness and shared decision making: a case for vulnerability. Patient Educ Couns 62:291–298PubMedCrossRef
8.
Zurück zum Zitat Bernheim J (2001) The doctor's dilemma between patient autonomy and physician beneficence at the end of life II. A patient–physician information and covenant (ICC) as a procedural–ethical solution. Ethiek en Maatschappij 4:114–121 (In Dutch) Bernheim J (2001) The doctor's dilemma between patient autonomy and physician beneficence at the end of life II. A patient–physician information and covenant (ICC) as a procedural–ethical solution. Ethiek en Maatschappij 4:114–121 (In Dutch)
9.
Zurück zum Zitat Jenkins V, Fallowfield L, Saul J (2001) Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 84:48–51PubMedCrossRef Jenkins V, Fallowfield L, Saul J (2001) Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 84:48–51PubMedCrossRef
10.
Zurück zum Zitat Gaston CM, Mitchell G (2005) Information giving and decision-making in patients with advanced cancer: a systematic review. Soc Sci Med 61:2252–2264PubMedCrossRef Gaston CM, Mitchell G (2005) Information giving and decision-making in patients with advanced cancer: a systematic review. Soc Sci Med 61:2252–2264PubMedCrossRef
11.
Zurück zum Zitat Davidson JR, Brundage MD, Feldman-Stewart D (1999) Lung cancer treatment decisions: patients' desires for participation and information. Psychooncology 8:511–520PubMedCrossRef Davidson JR, Brundage MD, Feldman-Stewart D (1999) Lung cancer treatment decisions: patients' desires for participation and information. Psychooncology 8:511–520PubMedCrossRef
12.
Zurück zum Zitat Gattellari M, Butow PN, Tattersall MH (2001) Sharing decisions in cancer care. Soc Sci Med 52:1865–1878PubMedCrossRef Gattellari M, Butow PN, Tattersall MH (2001) Sharing decisions in cancer care. Soc Sci Med 52:1865–1878PubMedCrossRef
13.
Zurück zum Zitat Curtis JR, Engelberg R, Young JP, Vig LK, Reinke LF, Wenrich MD, McGrath B, McCown E, Back AL (2008) An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer. J Palliat Med 11:610–620PubMedCrossRef Curtis JR, Engelberg R, Young JP, Vig LK, Reinke LF, Wenrich MD, McGrath B, McCown E, Back AL (2008) An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer. J Palliat Med 11:610–620PubMedCrossRef
14.
Zurück zum Zitat Butow PN, Maclean M, Dunn SM, Tattersall MH, Boyer MJ (1997) The dynamics of change: cancer patients' preferences for information, involvement and support. Ann Oncol 8:857–863PubMedCrossRef Butow PN, Maclean M, Dunn SM, Tattersall MH, Boyer MJ (1997) The dynamics of change: cancer patients' preferences for information, involvement and support. Ann Oncol 8:857–863PubMedCrossRef
15.
Zurück zum Zitat Wet betreffende palliatieve zorg 14 juni 2002. Belgisch Staatsblad 26 oktober 2002. [Law concerning palliative care June 14, 2002. Belgian official collection of the Laws October 26, 2002] (in Dutch) Wet betreffende palliatieve zorg 14 juni 2002. Belgisch Staatsblad 26 oktober 2002. [Law concerning palliative care June 14, 2002. Belgian official collection of the Laws October 26, 2002] (in Dutch)
16.
Zurück zum Zitat National cancer control programmes: policies and managerial guidelines (2002) Geneva: World Health Organisation National cancer control programmes: policies and managerial guidelines (2002) Geneva: World Health Organisation
17.
Zurück zum Zitat Bilsen J, Cohen J, Chambaere K, Pousset G, Onwuteaka-Philipsen BD, Mortier F, Deliens L (2009) Medical end-of-life practices under the euthanasia law in Belgium. N Engl J Med 361:1119–1121PubMedCrossRef Bilsen J, Cohen J, Chambaere K, Pousset G, Onwuteaka-Philipsen BD, Mortier F, Deliens L (2009) Medical end-of-life practices under the euthanasia law in Belgium. N Engl J Med 361:1119–1121PubMedCrossRef
18.
Zurück zum Zitat van der Heide A, Deliens L, Faisst K, Nilstun T, Norup M, Paci E, Van Der WG, van der Maas PJ (2003) End-of-life decision-making in six European countries: descriptive study. Lancet 362:345–350PubMedCrossRef van der Heide A, Deliens L, Faisst K, Nilstun T, Norup M, Paci E, Van Der WG, van der Maas PJ (2003) End-of-life decision-making in six European countries: descriptive study. Lancet 362:345–350PubMedCrossRef
19.
Zurück zum Zitat Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631PubMed Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631PubMed
20.
Zurück zum Zitat Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22:785–794PubMedCrossRef Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22:785–794PubMedCrossRef
21.
Zurück zum Zitat Wen KY, Gustafson DH (2004) Needs assessment for cancer patients and their families. Health Qual Life Outcome 2:11CrossRef Wen KY, Gustafson DH (2004) Needs assessment for cancer patients and their families. Health Qual Life Outcome 2:11CrossRef
22.
Zurück zum Zitat Kutner JS, Steiner JF, Corbett KK, Jahnigen DW, Barton PL (1999) Information needs in terminal illness. Soc Sci Med 48:1341–1352PubMedCrossRef Kutner JS, Steiner JF, Corbett KK, Jahnigen DW, Barton PL (1999) Information needs in terminal illness. Soc Sci Med 48:1341–1352PubMedCrossRef
23.
Zurück zum Zitat Degner LF, Sloan JA, Venkatesh P (1997) The control preferences scale. Can J Nurs Res 29:21–43PubMed Degner LF, Sloan JA, Venkatesh P (1997) The control preferences scale. Can J Nurs Res 29:21–43PubMed
24.
Zurück zum Zitat Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42:55–64PubMedCrossRef Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42:55–64PubMedCrossRef
25.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
26.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
27.
Zurück zum Zitat Cleveland WS, Devlin SJ (1988) Locally-weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 83:596–610CrossRef Cleveland WS, Devlin SJ (1988) Locally-weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 83:596–610CrossRef
28.
Zurück zum Zitat Parker SM, Clayton JM, Hancock K, Walder S, Butow PN, Carrick S, Currow D, Ghersi D, Glare P, Hagerty R, Tattersall MH (2007) A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. J Pain Symptom Manag 34:81–93CrossRef Parker SM, Clayton JM, Hancock K, Walder S, Butow PN, Carrick S, Currow D, Ghersi D, Glare P, Hagerty R, Tattersall MH (2007) A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. J Pain Symptom Manag 34:81–93CrossRef
29.
Zurück zum Zitat Street RL, Gordon HS (2008) Companion participation in cancer consultations. Psychooncology 17:244–251PubMedCrossRef Street RL, Gordon HS (2008) Companion participation in cancer consultations. Psychooncology 17:244–251PubMedCrossRef
30.
Zurück zum Zitat Degner LF, Sloan JA (1992) Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol 45:941–950PubMedCrossRef Degner LF, Sloan JA (1992) Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol 45:941–950PubMedCrossRef
Metadaten
Titel
Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients
verfasst von
Koen Pardon
R. Deschepper
R. Vander Stichele
J. L. Bernheim
F. Mortier
N. Bossuyt
D. Schallier
P. Germonpré
D. Galdermans
W. Van Kerckhoven
L. Deliens
on behalf of the EOLIC-consortium
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 10/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1369-4

Weitere Artikel der Ausgabe 10/2012

Supportive Care in Cancer 10/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.